Compare and Contrast: GLP-1 Receptor Agonists Access and Cardiovascular Outcomes

17 Feb 20264 min read0 viewsVerified Feed

GIST (Key Takeaways)

As the onslaught of anti-obesity drugs hit the market in recent years, more research is being released about their potential side effects as well as their benefits. Endocrine News investigates two of these studies to gain more insight to how these “miracle drugs” could affect cardiac health.
At a Glance Among patients with type 2 diabetes and atherosclerotic CVD, the dual agonist tirzepatide was noninferior to dulaglutide with respect to a composite of death from cardiovascular causes, MI, or stroke, and a prespecified secondary analysis suggested a possible lower incidence of death from any cause and of death from non-cardiovascular causes with tirzepatide. Among GLP-1RAs, semaglutide and liraglutide should be prioritized, if possible, for cardiovascular risk reduction for patients with type 2 diabetes and moderate (not just high) cardiovascular risk.
However, the most important takeaway is that GLP-1RAs can be used in patients with type 2 diabetes not only with high, but also those with moderate, cardiovascular risk.

Endocrine News published a clinical update in Research Highlights on 17 Feb 2026.

The item focuses on Compare and Contrast: As Glucagon-Like Peptide-1 Receptor Agonist Access Expands, Comparative Heart Outcomes Matter.

Review the original article for the full source wording and details.

Read the full original publication from the source journal or publisher link below.

Feed Metadata

Source

Endocrine News